CHO Pharma, Inc.
TTPEX:6586107.50
TWD
-7.00
(-6.11%)
ISIN
TW0006586001
Return %
Stock
S&P 500
1Y
198.20
14.20
3Y
39.79
81.12
5Y
48.69
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Tsung I Wu
- Full Time Employees
- 35
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Building C Taipei TPE Taiwan 115202
- IPO Date
- Sep 27, 2017
- Website
- chopharma.com
- Similar Companies
- Business
- CHO Pharma, Inc. is a Taiwan-based biopharmaceutical firm engaged in the research, development, and commercialization of innovative therapeutics, leveraging its proprietary glycan engineering technologies. The company is dedicated to advancing a portfolio that includes advanced glycoengineered biobetters and site-specific antibody-drug conjugates (ADCs), alongside novel antibodies and vaccines designed to target specific carbohydrate antigens. Central to its innovation is the CHOptimax™ glycoengineering platform, a patented enzymatic one-pot process that efficiently transforms naked antibodies into enhanced glycoengineered biobetters or glycosite-specific ADCs. This platform, recently recognized as the "Best Platform Technology" in Biologic World Taiwan 2025, offers precise control over glycosylation, leading to improved efficacy and a broader therapeutic window for next-generation antibody conjugates. CHO Pharma also provides services for producing glycoengineered antibodies and glycosite-specific ADCs for research and preclinical evaluation. The company's pipeline features several programs in various stages of development. CHO-H01, a glycoengineered biobetter antibody targeting CD20, is actively recruiting for its Phase I/IIa clinical trials for individuals with refractory non-Hodgkin lymphoma. This therapeutic is notable for its homogeneous, fully α2,6-sialylated biantennary glycan, showing significantly increased antibody-dependent cellular cytotoxicity (ADCC) activity in preclinical studies compared to its non-glycoengineered counterpart. CHO-A04, a humanized monoclonal antibody designed to target the SSEA-4 glycosphingolipid found on various tumor cells and cancer stem cells, received U.S. FDA approval for a Phase I clinical trial in August 2025 and is currently recruiting subjects with advanced solid tumors. Moreover, CHO-V08, a bivalent preventative vaccine against hypervirulent Klebsiella pneumoniae (K1 and K2 serotypes), received U.S. FDA approval for Phase I clinical trials in April 2024 and commenced recruitment in June 2025 to assess its safety and immunogenicity in healthy adults. In preclinical stages, CHO-H02 is being developed as a next-generation antibody drug targeting HER2 for solid tumors such as breast, bladder, pancreatic, ovarian, and gastric cancers, with several candidates under evaluation. Additionally, CHO-H03 is an antibody drug in preclinical development aimed at mitigating inflammatory conditions in autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, and Crohn's disease, utilizing CHOptimax™ technology to enhance FcγR binding and induce regulatory macrophages. The company, founded in 2012 and based in Taipei City, Taiwan, operates on a double-engine business model, focusing on both technology platform licensing and the advancement of its proprietary drug candidates, aiming to become a global leader in glycan technology biotechnical pharmaceuticals. Recent strategic alliances, such as with T-E Med, Inc. in September 2023, further strengthen its capabilities in developing advanced antibody-drug conjugates.